1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsProgram closed to new fund managers but investee companies may contact existing licensed fund managers (Brandon Capital Partners, OneVentures Management, BioScience Managers) on a rolling basis.
Biomedical Translation Fund (BTF) is sponsored by Australian Government (managed by AusIndustry). The Biomedical Translation Fund (BTF) is an equity co-investment venture capital program designed to invest in promising biomedical discoveries and assist in their commercialisation.
Get alerted about grants like this
Get emailed when new opportunities from “Australian Government (managed by AusIndustry)” or related funders appear. Free, weekly, unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
Biomedical Translation Fund (BTF) | business. gov.au Biomedical Translation Fund (BTF) The Biomedical Translation Fund (BTF) provides companies with venture capital through licensed private sector fund managers. It will help you to develop your biomedical discoveries into tangible products, services and outcomes.
Application detail: As an investee company, you may contact a licensed fund manager at any time to seek investment. The program is now closed to new fund managers. Investment to develop and commercialise biomedical discoveries.
Early-stage biomedical companies. The BTF fund is an equity co-investment venture capital program.
The BTF Program policy objectives are to: invest in promising biomedical discoveries and assist in their commercialisation encourage the development of companies commercialising biomedical discoveries by addressing capital and management constraints The program supports biomedical discoveries that commercialise health and medical research outcomes.
This will improve the health and wellbeing of Australians through targeted investment in prevention, diagnosis and treatment. The discoveries can be therapeutic, medical or pharmaceutical. They can be a product, process, service (including digital health services), technology or procedure.
The funding is available through 3 licensed private sector venture capital fund managers. The BTF fund managers screen investment proposals and make venture capital investments. They also provide Australian biomedical companies with the expertise and access to networks to be a success.
Each BTF fund manager will build a portfolio of investments. They'll invest in companies that develop and commercialise innovative science to improve the health and wellbeing of Australians. The government announced this fund in the National Innovation and Science Agenda.
A total of $501. 25 million is available through the Biomedical Translation Fund. A total of $250 million is from Commonwealth capital and $251.
25 million is from private sector capital. AusIndustry is delivering the BTF on behalf of the Australian Government Department of Health. What are the eligibility criteria for the BTF?
This program doesn't automatically provide capital to all companies that satisfy the eligible investment criteria. Instead, we have licensed 3 fund managers to make investment decisions.
At the time of the first investment, you must either be: already working on a biomedical discovery planning to work on a biomedical discovery through a BTF investment have a majority of your employees and assets inside Australia plan to use the whole of the initial investment within Australia have an average annual revenue over the previous two years of below $25 million per year have an Australian business number (ABN) be incorporated under the Corporations Act 2001 be providing all the goods or services you produce to persons who are not Associates For full details on eligible investee companies, refer to section 8.
6 in the BTF Program Guidelines . For a list of ineligible investments please refer to the BTF Programme guidelines . There are 3 licensed private sector fund managers who are responsible for investment decision making.
If you believe your company is eligible and you are seeking an equity investment, you should contact one of the BTF fund managers directly. Before contacting the fund manager, you should know who they are and what investments they have previously made. info@brandoncapital.
com. au Entrepreneurs@one-ventures. com Chief Investment Officer/Director info@biosciencemanagers.
com How do we assess your application? The BTF fund managers will decide on an applicant’s eligibility based on criteria in the BTF Programme Guidelines. Not all companies who are eligible will receive investment.
View a list of investee companies that have received investment commitment from the Biomedical Translation Fund (BTF). Let us answer your question over the phone, email or live chat. Monday to Friday, 8am to 6pm across Australia The BTF provides innovative biomedical companies with venture capital support.
Hear how this support has helped companies on their journey. BioScience Managers and Cynata Brandon Capital and George Medicines - improving hypertension management Find out how George Medicines, with the support of Brandon Capital, is developing a treatment to help better manage hypertension. Thanks for sharing your feedback with us.
I couldn't find what I was looking for The layout or style made it hard to read The information wasn't useful to me The information was confusing Provide your feedback below.
We can't respond to queries submitted through this form, so please don't include any personal details (maximum 1,500 characters) Recaptcha validation failed <div class='utility-item d-flex align-items-center gap-3 lh-lg'><span class='facebook d-flex icon icon-16'><svg aria-hidden="true" xmlns="http://www. w3. org/2000/svg" viewBox="0 0 7.
466 16"> <path d="M4. 964,16V8H7. 173l.
293-2. 757h-2. 5l0-1.
38c0-. 719. 068-1.
1,1. 1-1. 1H7.
45V0H5. 241C2. 588,0,1.
654,1. 338,1. 654,3.
587V5. 242H0V8H1. 654v8Z" fill="#4569a0"></path> </svg></span><a href='#' class='share-text fw-semibold' id='share-fb' data-testid='utility-share' data-sharelink='https://www.
facebook. com/share. php?
u=' data-personalise-click="{341D5184-39D3-406E-BAAF-0DACD1AFED17}">Facebook</a></div><div class='utility-item d-flex align-items-center gap-3 lh-lg'><span class='linkedin d-flex icon icon-16'><svg aria-hidden="true" viewBox="0 0 16 16" xmlns="http://www. w3. org/2000/svg"><path d="M4.
055 6. 069v9. 477H.
901V6. 069h3. 154zm.
208-2. 932c0 . 91-.
685 1. 638-1. 785 1.
638h-. 02C1. 4 4.
775. 715 4. 047.
715 3. 137c0-. 93.
705-1. 637 1. 784-1.
637 1. 08 0 1. 744.
708 1. 764 1. 637zm11.
168 6. 975v5. 434h-3.
155v-5. 07c0-1. 274-.
456-2. 143-1. 598-2.
143-. 871 0-1. 39.
586-1. 618 1. 152-.
084. 202-. 104.
485-. 104. 768v5.
293H5. 8s. 042-8.
588 0-9. 477h3. 155V7.
41c. 419-. 645 1.
168-1. 565 2. 843-1.
565 2. 076 0 3. 632 1.
355 3. 632 4. 266z" fill="#0077b5"></path></svg></span><a href='#' class='share-text fw-semibold' id='share-li' data-testid='utility-share' data-sharelink='https://www.
linkedin. com/sharing/share-offsite/? url=' data-personalise-click="{B315048D-EEA4-42FA-8FD9-60EA17E81304}">LinkedIn</a></div><div class='utility-item d-flex align-items-center gap-3 lh-lg'><span class='x-logo d-flex icon icon-16'><svg aria-hidden="true" xmlns="http://www.
w3. org/2000/svg" viewBox="0 0 22 22. 483"><path d="M13.
093,9. 52,21. 283,0H19.
342L12. 231,8. 266,6.
551,0H0L8. 589,12. 5,0,22.
483H1. 941l7. 51-8.
729,6,8. 729H22L13. 093,9.
52Zm-2. 658,3. 09-.
87-1. 245L2. 64,1.
461H5. 621l5. 588,7.
993. 87,1. 245,7.
264,10. 39H16. 362l-5.
927-8. 478Z"></path></svg></span><a href='#' class='share-text fw-semibold' id='share-x' data-testid='utility-share' data-sharelink='https://x. com/intent/post?
url=' data-personalise-click="{63B8C6C5-FF72-4B3A-9A95-9D50A10E2323}">X</a></div> " aria-expanded="false" data-testid="utility-item">
According to the current listing, eligibility includes: Early-stage biomedical companies with average annual revenue below $25M, an Australian Business Number (ABN), incorporated under Australia's Corporations Act 2001, with majority employees/assets in Australia. Confirm the full requirements in the official notice before applying.
The current listing shows $501.25 million total fund. Verify award ceilings, matching requirements, and allowable costs in the official notice.
Biomedical Translation Fund (BTF) is funded by Australian Government (managed by AusIndustry). Verify program details on the funder's official page before applying.
This listing is flagged as international in scope. Check the official notice for country-specific restrictions before applying.
Applications go through the funder's official portal — the Apply Now link on this page goes there directly.
NCI Continuing Umbrella of Research Experiences (CURE) Academic Career Excellence (ACE) Award (K32) is a grant from the National Cancer Institute (NCI) that funds early postdoctoral fellows from diverse backgrounds, including underrepresented groups, to pursue research training in cancer-related fields. The K32 award supports fellows within 12 months prior to transitioning into, or within the first two years of, a postdoctoral position. The program, operated through NCI's Center to Reduce Cancer Health Disparities (CRCHD), aims to enhance the pool of qualified diverse cancer researchers. Beginning with the June 12, 2025 due date, the CURE ACE Award is available in both Independent Clinical Trial Required and Independent Clinical Trial Not Allowed versions. Eligible applicants must be U.S. citizens or permanent residents at time of award.
NICHD Small Research Grant Program (R03 Basic Experimental Studies with Humans Required) is sponsored by Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD). Supports clinical trials that prospectively assign human participants to conditions to assess biomedical or behavioral outcomes, focusing on fundamental aspects of phenomena without specific application towards processes or products in mind.
On June 8, HHS and GSA launched a new Grants Management Special Item Number — SIN 518210GM — creating a government-wide buying lane for modern, standards-compliant grants software tied to more than $1.2 trillion in annual awards. It reads like procurement plumbing. For grantees, govtech vendors, and the future of grant data interoperability, it is anything but.
Read articleThe political pre-issuance review provision drew the headlines. But the more consequential change is procedural — turning the Uniform Guidance into the Uniform Grants Regulation removes every internal speed bump on future OMB grant rulemaking.
Read articleBeyond the headline housing and science cuts, the FY2027 budget would eliminate DOJ state/local law enforcement grants, EPA clean water revolving funds, FEMA disaster preparedness, EDA economic development, NTIA digital equity, and more. The complete analysis for local government grant seekers.
Read article